Article
Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 30 Apr 2026
Obeng Billal Musah, Hutchinson Jolie, Shaik Ansari, Chetchotisakd Ploenchan, Azwa Iskandar, Wulan Wahyu Nawang, Kumarasamy Nagalingeswaran, Wolff Marcelo, Bruguera José, Losso Marcelo, Kaplan Richard, Diallo Mariama Sadjo, Eriobu Nnakelu, Musoro Godfrey, Kumalawati July, Badamasi Abba, Fitriah Munawaroh, Mulya Deshinta Putri, Law Matthew, Matthews Gail, Di Giallonardo Francesca, Kelleher Anthony Dominic
Abstract excerpt
BACKGROUND: D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) was a phase 3b/4 randomized clinical trial designed to assess second-line treatment options systematically. This substudy evaluated the distribution of drug resistance mutations (DRMs) before treatment randomization in individuals failing first-line therapy. METHODS: From a total of 826 participants across 14 countries, 727...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.